FDA OKs Rybelsus to Reduce CV Risk in T2D – Medscape

1. FDA OKs Rybelsus to Reduce CV Risk in T2D  Medscape
2. First oral GLP-1 cuts cardiovascular risk by 14% – and it’s now FDA-approved  New Atlas
3. Novo GLP-1 pill OK’d in U.S. for heart disease risk (NVO:NYSE)  Seeking Alpha
4. FDA approves Novo Nordisk’s oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event  BioSpace
5. Popular weight loss drug reduces heart disease death risk by 26 percent  Earth.com

Continue Reading